Somatostatin infusion and hemodynamic changes in patients with non-variceal upper gastrointestinal bleeding: A pilot study

Simple item page
dc.contributor.authorSaruç M.
dc.contributor.authorCan M.
dc.contributor.authorKüçükmetin N.
dc.contributor.authorTuzcuoglu I.
dc.contributor.authorTarhan S.
dc.contributor.authorGöktan C.
dc.contributor.authorYüceyar H.
dc.date.accessioned2024-07-22T08:24:51Z
dc.date.available2024-07-22T08:24:51Z
dc.date.issued2003
dc.description.abstractBackground: Intravenous somatostatin decreases acid secretion, splanchnic blood flow, and portal pressure, but the evidence for its efficacy in the treatment of non-variceal upper gastrointestinal bleeding has been mixed. We aimed to evaluate the vasoactive effect and possible mechanisms of somatostatin infusion in the cessation of non-variceal upper gastrointestinal bleeding. Material/Methods: Patients with non-variceal upper gastrointestinal bleeding without portal hypertension were enrolled in the study. They were given somatostatin infusion in a dose of 250 μgr/hour for 72 hours. Superior mesenteric arterial average flow velocity (SMA-V), SMA pulsatility index (SMA-PI), portal venous volume flow (PV-F), and renal artery resistance index (RA-RI) were measured two times for each patient by Doppler ultrasound; oncee on the first day of infusion therapy and again 6 hours or more after stopping the infusion. Results: 21 patients (12 male, mean age 44.1±9.9) with bleeding peptic ulcer were enrolled. During somatostatin infusion, PV-F was 33.7±19.7 cm3/sec. After stopping infusion, it increased to 56.3±16.0 cm3/sec (p=0.001). SMA-V was 39.7±13.1 cm/ sec and 64.4±15.1 cm/sec during somatostatin infusion and after cessation of somatostatin respectively (p=0.01). SMA-PI was 2.0±0.8 during somatostatin infusion but 2.8±0.8 without somatostatin infusion (p=0.02). However, RA-RI showed no difference between states with or without somatostatin infusion (p>0.05). Conclusions: Somatostatin infusion causes a decrease in arterial blood flow to the stomach and duodenum in patients with non-variceal upper gastrointestinal bleeding without portal hypertension. Somatostatin therapy also decreases portal blood flow while not altering renal blood.
dc.identifier.issn12341010
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20158
dc.language.isoEnglish
dc.subjectAdult
dc.subjectDuodenum
dc.subjectEsophageal and Gastric Varices
dc.subjectGastrointestinal Hemorrhage
dc.subjectHemodynamic Processes
dc.subjectHormones
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPilot Projects
dc.subjectRegional Blood Flow
dc.subjectSomatostatin
dc.subjectStatistics
dc.subjectStomach
dc.subjectTreatment Outcome
dc.subjectsomatostatin
dc.subjectadult
dc.subjectartery blood flow
dc.subjectartery resistance
dc.subjectarticle
dc.subjectblood flow velocity
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectDoppler echography
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug infusion
dc.subjectfemale
dc.subjecthemodynamics
dc.subjecthuman
dc.subjectintestine blood flow
dc.subjectkidney artery
dc.subjectmale
dc.subjectpeptic ulcer bleeding
dc.subjectpilot study
dc.subjectportal vein blood flow
dc.subjectpulse wave
dc.subjectstomach blood flow
dc.subjectsuperior mesenteric artery
dc.subjectupper gastrointestinal bleeding
dc.titleSomatostatin infusion and hemodynamic changes in patients with non-variceal upper gastrointestinal bleeding: A pilot study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu